Cash and cash equivalents and short-term investments were $259.7M as of December 31, 2023. Annexon continues to expect its cash, cash equivalents and marketable securities as of December 31, 2023, to be sufficient to fund the company’s planned operating expenses into mid-2026. “Our strong execution in 2023 across our three priority programs successfully achieved key clinical and regulatory milestones and created a solid foundation from which to reach several important upcoming catalysts in 2024,” said Douglas Love, president and chief executive officer of Annexon. “Importantly, our approach in blocking C1q to stop classical complement-driven neuroinflammation in diseases of the body, brain and eye continues to show unique and consistent functional outcomes across our pipeline programs.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX:
- Annexon options imply 24.7% move in share price post-earnings
- Annexon participates in a conference call with JPMorgan
- Annexon Biosciences, Inc. (ANNX) Q4 Earnings Cheat Sheet
- Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
- J.P. Morgan Predicts up to 140% Rally for These 2 ‘Strong Buy’ Stocks